Pre-made Faricimab biosimilar ( Bispecific mAb, anti-VEGFA;ANGPT2 therapeutic antibody) - benchmark reference antibody
Cat No.: GMP-Bios-ab-204
Anti-VEGFA;ANGPT2 therapeutic antibody (Pre-made Faricimab biosimilar,Bispecific mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Faricimab (INN) is a bispecific monoclonal antibody that is being investigated for diabetic macular edema.
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Anti-VEGFA;ANGPT2 therapeutic antibody (Pre-made Faricimab biosimilar,Bispecific mAb)|
|Highest_Clin_Trial (Jan '20)||Phase-III|
|100% SI Structure||1cz8:HL:YX;None|
|99% SI Structure||None;None|
|95-98% SI Structure||1bj1:HL:KJ/6bft:AB:HL;4iml:AB:HL/4imk:AD:BC|
|Conditions Active||Diabetic macular oedema;Wet age-related macular degeneration;Retinal oedema|
|Development Tech||Dual-Affinity Re-Targeting Technology|